Charts

21 Nov, 2022
12:00
Seeking Alpha
17 Nov, 2022
23:14
Seeking Alpha

News

24 Nov, 2022
InvestorPlace - Stock Market News, Stock Advice & Trading Tips These three biotech stocks could be among the best ways to play this uncertain market for those looking for long-term growth. The post 3 Biotech Stocks Smart Investors Should Be Buying Up Now appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
23 Nov, 2022
U.S. stocks closed higher on Tuesday, with the Dow Jones gaining around 400 points. Here is the list of some big stocks recording losses ...
22 Nov, 2022
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside discussion at the 34th Annual Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 10:00 a.m. ET in New York City.
21 Nov, 2022
Gainers AGBA Group Holding Limited (NASDAQ: AGBA) gained 50.7% to close at $6.78 on Friday. FOXO Technologies Inc. (NYSE: FOXO) ...
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 200 points. Here is the list of some big stocks recording gains ...
20 Nov, 2022
Recent analyst upgrades suggest these stocks can triple your money or better.
18 Nov, 2022
Gainers PaxMedica, Inc. (NASDAQ: PXMD) gained 53.5% to $2.38 after the company announced an equity investment agreement for up to ...
Gainers IVERIC bio (NASDAQ:ISEE) shares increased by 26.7% to $21.84 during Friday's regular session. As of 12:30 EST, this security is ...
The FDA's CRDAC recommends granting marketing approval to Ardelyx's (ARDX) oral pill to control serum phosphorus in adult patients with chronic kidney disease on dialysis.
Piper Sandlerraised its price target onArdelyx Inc(NASDAQ: ARDX) to $8 from $3 and upgraded toOverweight from ...
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. Elevate Credit, Inc. (NYSE: ELVT) ...
U.S. stocks closed slightly lower on Thursday, with the S&P 500 dropping around 0.3%. Here is the list of some big stocks recording ...
17 Nov, 2022
Gainers IVERIC bio (NASDAQ:ISEE) shares rose 18.8% to $20.48 during Thursday's after-market session. Today's trading volume for this ...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday. The Dow traded ...
Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities ...
In trading on Thursday, shares of Ardelyx Inc (ARDX) touched a new 52-week high of $1.98/share. That's a 304.08% rise, or $1.49 per share from the 52-week low of $0.49 set back on 06/16/2022..
Stocks are firmly lower midday, as bond yields rise following hawkish comments from St. Louis Federal Reserve President James Bullard.
Gainers Ardelyx (NASDAQ:ARDX) shares moved upwards by 53.3% to $1.87 during Thursday's regular session. Trading volume for Ardelyx's ...
Ardelyx's (NASDAQ:ARDX) short percent of float has fallen 23.89% since its last report. The company recently reported that it has ...
U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday. The Dow traded down 0.53% to ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CytomX Therapeutics (CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (REGN). The post Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ardelyx (ARDX) stock is taking off on Thursday after an advisory committee to the FDA voted in favor of its kidney disease drug. The post Why Is Ardelyx (ARDX) Stock Up 38% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
In a surprise move, a committee of the agency’s outside advisors voted in favor of the proposition that the drug's benefits outweigh its risks.
Upgrades Wolfe Research upgraded the previous rating for Matson Inc (NYSE:MATX) from Underperform to Peer Perform. In the third ...
CNBC Despite NATO Coming In Support Of Ukraine, Kyiv Asserts It Does Not Take Blame For Poland Missile Attack Ukraine's ...
Gainers Ardelyx (NASDAQ:ARDX) stock rose 61.5% to $1.97 during Thursday's pre-market session. The company's market cap stands at $369.2 ...
Gainers Ardelyx Inc (NASDAQ: ARDX) shares rose 81.2% to $2.21 in pre-market trading as the company said the FDA Advisory Committee ...
The FDA's Cardiovascular and Renal Drugs Advisory Committeevoted in favorofArdelyx Inc's(NASDAQ: ...
Shares of Ardelyx Inc. rocketed 75.4% on heavy volume toward a 16-month high in premarket trading Thursday, after an advisory panel of the U.S. Food and Drug Administration voted that benefits of the biopharmaceutical company's treatment for chronic kidney disease (CKD) on dialysis, XPHOZAH, outweigh the risks. Trading volume was 11.7 million shares ahead of the open, compared with the full-day average of 4.3 million shares. That made Ardelyx's stock the biggest gainer and most active in the pre
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading ...
16 Nov, 2022
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced the vote of the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting for XPHOZAH for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. The CRDAC voted nine to four that the benefits o
The FDA rejected the drug for kidney disease patients, but the company appealed. After an advisory panel recommended approval Wednesday, the drug's fate again rests with the FDA.
A panel of advisers to the U.S. health regulator on Wednesday recommended the approval of Ardelyx Inc's drug for chronic kidney disease patients on dialysis, more than a year after it was initially rejected. The Food and Drug Administration's advisory panel voted 9-4 in favor of the drug, tenapanor, to be administered as a single therapy for treating high phosphate levels in the blood of patients on dialysis. The advisers also voted 10-2 in favor of the drug's use alongside existing treatment.
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Nasdaq has halted trading of the Company's common stock.
14 Nov, 2022
The FDA's Cardiovascular and Renal Drugs Advisory Committee isscheduled to meetWednesday, November 16, to ...
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated ...
U.S. Food and Drug Administration staff reviewers on Monday raised concerns over unclear benefits of Ardelyx Inc's drug for kidney disease patients, but the company's shares rose 20% on expectations over a possible approval. The FDA's staff reviewers said, "the magnitude of treatment effect appears less than that observed with approved drugs," in briefing documents released on Monday. However, the concerns were in line with expectations, said Citi analysts, adding that the documents set the tone for a positive discussion when the FDA's outside advisers meet on Wednesday to weigh data on the drug.
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping more than 100 points on Monday. Following the market ...
09 Nov, 2022
Ardelyx ( NASDAQ:ARDX ) Third Quarter 2022 Results Key Financial Results Net loss: US$22.9m (loss narrowed by 48% from...
08 Nov, 2022
If you want to know who really controls Ardelyx, Inc. ( NASDAQ:ARDX ), then you'll have to look at the makeup of its...
04 Nov, 2022
Ardelyx, Inc. (Nasdaq: ARDX) in partnership with the National Kidney Foundation (NKF), today announced results from a survey of patients with chronic kidney disease (CKD) on dialysis conducted to better understand patients' experience managing serum phosphorus levels. The survey found that more than 80% of respondents struggle to manage their serum phosphorus levels, with more than 90% citing a need for new treatment options.
03 Nov, 2022
Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 86.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business updates and financial results for the third quarter ended September 30, 2022.
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that new analyses of data from its three Phase 3 trials supporting the clinical utility of XPHOZAH (tenapanor) will be presented at the American Society of Nephrology (ASN) Kidney Week 2022, taking place in Orlando, Florida from November 3-6, 2022. XPHOZAH is an investigational first-
02 Nov, 2022
21:35
Seeking Alpha
15:15
FinancialContent
Ardelyx (NASDAQ:ARDX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know ...
01 Nov, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or ...
29 Oct, 2022
21:34
FinancialContent
The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the pace with technology.
24 Oct, 2022
06:13
Seeking Alpha
18 Oct, 2022
12 Oct, 2022
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) rose 43.2% to $0.2097 in pre-market trading after jumping over 16% on ...
16 Sep, 2022
06 Sep, 2022
San Diego, CA -- (SBWIRE) -- 09/06/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Ardelyx, Inc.
03 Aug, 2022
21:35
Seeking Alpha
21 Jun, 2022
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 ...
13 Jun, 2022
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Arch Resources Inc (ARCH), where a total volume of 8,726 contracts has been traded thus far today, a contract volume which is representative of approximately 872,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 112.5% of ARCH's average daily trading volume over the past month, of 775,890 shares..
03 Jun, 2022
San Diego, CA -- (SBWIRE) -- 06/03/2022 -- An investorsin shares of Ardelyx, Inc. (NASDAQ:ARDX) filed a lawsuit against certain directors of Ardelyx, Inc over alleged breaches of fiduciary duties.
25 May, 2022
Gainers The Singing Machine Company, Inc. (NASDAQ: MICS) shares rose 47.3% to $4.05 in pre-market trading. Motus GI Holdings, ...
24 May, 2022
Gainers Motus GI Hldgs (NASDAQ:MOTS) shares increased by 62.3% to $0.42 during Tuesday's after-market session. At the close, Motus GI ...
06 May, 2022
Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of ...
04 May, 2022
21:35
Seeking Alpha
26 Apr, 2022
08:58
FinancialContent
Gainers Nkarta, Inc. (NASDAQ: NKTX) shares climbed 140.9% to close at $18.72 on Monday after the company announced Phase 1 data ...
25 Apr, 2022
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Deere & Co. (DE), where a total of 20,733 contracts have traded so far, representing approximately 2.1 million underlying shares..
U.S. stocks pared losses toward the end of trading, with the Nasdaq Composite gaining around 70 pointson Monday. The Dow traded ...
Gainers Nkarta (NASDAQ:NKTX) stock rose 109.4% to $16.27 during Monday's regular session. Trading volume for ...
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 400 points on Monday. The Dow traded down ...
Gainers Nkarta, Inc. (NASDAQ: NKTX) shares jumped 108.6% to $16.21 after the company announced Phase 1 data from independent dose ...
15:38
FinancialContent
Ardelyx Inc (NASDAQ: ARDX) shares are trading higher by 29.32% at $0.97 after the company reported it received an interim response from ...
The FDA's Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), hasprovided an interim ...
Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 52.5% to $1.86 during Monday's pre-market session. The company's ...
27 Feb, 2022
22:35
Seeking Alpha
28 Jan, 2022

Related Articles